Avantor (NYSE:AVTR) Price Target Raised to $15.00

Avantor (NYSE:AVTR) had its target price increased by Morgan Stanley from $14.00 to $15.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Barclays boosted their price objective on shares of Avantor from $13.00 to $15.00 and gave the company an “underweight” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada raised their target price on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Sanford C. Bernstein began coverage on Avantor in a report on Friday, June 26th. They issued a “market perform” rating and a $10.50 target price on the stock. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 target price on the stock in a research report on Wednesday, July 29th. Finally, Wolfe Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Avantor currently has a consensus rating of “Hold” and a consensus target price of $13.06.

Avantor Stock Performance

AVTR opened at $16.08 on Tuesday. The company’s 50 day moving average is $14.85 and its 200 day moving average is $11.37. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.87 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 8.93 and a beta of 0.94. Avantor has a 12-month low of $7.26 and a 12-month high of $16.38.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same period in the prior year, the company earned $0.24 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, equities research analysts predict that Avantor will post 0.81 EPS for the current year.

Institutional Investors Weigh In On Avantor

Institutional investors have recently added to or reduced their stakes in the stock. SJS Investment Consulting Inc. increased its stake in Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after acquiring an additional 4,927 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of Avantor by 72.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after acquiring an additional 1,176 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Avantor by 901.4% during the 2nd quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock valued at $58,000 after acquiring an additional 5,273 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Avantor by 21.4% during the 1st quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock valued at $66,000 after acquiring an additional 1,491 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of Avantor during the 2nd quarter valued at approximately $74,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.